MUMBAI, India, April 17 -- Intellectual Property India has published a patent application (202621022778 A) filed by Ansicht Voneden, Satara, Maharashtra, on Feb. 26, for 'modular receptor-ligand platform for programmable sequential, parallel, and gradient signaling control using multi-format receptor and ligand module.'
Inventor(s) include Dr. Ajinkya Inamdar.
The application for the patent was published on April 17, under issue no. 16/2026.
According to the abstract released by the Intellectual Property India: "The instant disclosure provides a universal therapeutic platform for modulating biological signaling in mammalian tissues through the administration of engineered signaling modules comprising receptors, ligands, constitutively active variants, decoy variants, or combinations thereof. The invention enables controlled activation, suppression, restoration, or rebalancing of cellular pathways by administering the signaling modules sequentially, simultaneously, or in defined temporal or spatial patterns. The signaling modules may be formulated using nucleic acids, viral or non-viral vectors, recombinant proteins, engineered cells, extracellular vesicles, nanoparticles, biomaterials, or combinations thereof. The invention further encompasses therapeutic compositions, systems, and dosing regimens designed to alter cellular signaling without requiring permanent genetic modification. The disclosed platform supports modular assembly of receptor-ligand constructs to achieve localized or systemic biological effects across multiple tissue types and disease states."
Disclaimer: Curated by HT Syndication.
